Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | GPR132 | Q9UNW8 | 14/20 | 0.51 |
| ▸ | CMKLR2 | P46091 | 1/20 | 0.49 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28011530 | 0.86 | MAPK1 (0.64) | MAPK1GPR132CMKLR2CMKLR1HTR1A | |
| SCHEMBL22964220 | 0.83 | SMN1; SMN2 (0.52) | MAPK1GPR132 | |
| SCHEMBL23838435 | 0.83 | MAOB (0.57) | — | |
| SCHEMBL22964344 | 0.80 | MAPK1 (0.58) | MAPK1GPR132CMKLR2CMKLR1 | |
| SCHEMBL21477258 | 0.79 | MAPK1 (0.57) | MAPK1GPR132CMKLR2CMKLR1HTR1A | |
| SCHEMBL13462940 | 0.79 | MAPK1 (0.60) | MAPK1GPR132HTR1ADRD2GRM2 | |
| SCHEMBL3998456 | 0.79 | MAOB (0.66) | MAPK1GPR132CMKLR2CMKLR1 | |
| SCHEMBL791886 | 0.79 | MAOB (0.66) | MAPK1GPR132HTR1ADRD2 | |
| SCHEMBL13452125 | 0.79 | MAPK1 (0.57) | MAPK1GPR132HTR1ADRD2GRM2 | |
| SCHEMBL10032807 | 0.78 | APP (0.59) | MAPK1GPR132CMKLR2CMKLR1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961231-B2 | NTCP inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-03-30 | — | — | US | disclosed |
| US-20210040072-A1 | NTCP Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040072-A1 | NTCP Inhibitors | HAVCR2, NPC1, HMGCR | MAPK1 2737/4885GPR132 3289/4885CMKLR2 2201/4885 |
| US-10961231-B2 | NTCP inhibitors | HAVCR2, NPC1, HMGCR | MAPK1 2737/4885GPR132 3289/4885CMKLR2 2201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.